Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Establishment of a Microfluidic Based Liquid Biopsy Platform for Recurrent/Metastatic Head and Neck Cancers Prognostication Using NK Cell IFN-γ Expression and CTM Correlation With DS-SACA Chip

NCT06678724 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT06678724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06678724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Establishment of a Microfluidic Based Liquid Biopsy Platform for Recurrent/Metastatic Head and Neck Cancers Prognostication Using NK Cell IFN-γ Expression and CTM Correlation With DS-SACA Chip
Lead sponsor
National Taiwan University Hospital
Phase
Observational
Overall status
Recruiting
Start date
January 1, 2025
Completion date
December 31, 2027
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer metastatic, head and neck cancers- squamous cell, recurrent head and neck squamous cell carcinoma